Nima Farzan
CIK 1808296 · CHIEF EXECUTIVE OFFICER · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$99.1K
Companies
2
Total Filings
13
Lifetime Open-Market Net
-$28.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KROS | Director | 9,767 | $10.15 | $99.1K | -$28.2K | 8 | 2026-06-08 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Chief Executive Officer | — | $2.65 | — | $0 | 4 | 2023-02-15 |
Recent Filings · Page 2 of 2
13 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-03 | KROS | Grant (A) | — | $0 | EDGAR |
| 2021-02-16 | Kinnate Biopharma Inc. (KNTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-29 | KROS | Grant (A) | — | $0 | EDGAR |
Showing 11–13 of 13
Prev
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.